Metrics as of 10/17/2026, 08:47 AM (Berlin time), refresh in progress.
Exicure Stock
Exicure, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Jungsoo Kim
- Employees
- 1
- Market cap
- $7 M
- IPO
- 22/05/2018
Exicure, Inc. does not have significant operations. Previously, it focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The company has a co-development agreement with Adbiotech Co., Ltd. to explore combination therapies based on Burixafor (GPC-100) across multiple…
Exicure stock: price history
1D
+0.0%
1W
+6.7%
1M
-15.8%
6M
-70.4%
YTD
-79.3%
1Y
-77.1%
2Y
-61.5%
5Y
-99.4%
10Y
–
Next earnings date
Next earnings date
12/11/2026 (in 26 days)
Volatility around earnings
~19% stronger price swings than usual
Ask the agents about Exicure
Analyst assessment of Exicure
PRICE TARGET LOW
US$12.00
CONSENSUS
US$12.00
MEDIAN
US$12.00
PRICE TARGET HIGH
US$12.00
0
STRONG BUY
5
BUY
1
HOLD
0
SELL
0
STRONG SELL
6
TOTAL · Buy
As of: 16/08/2022
Exicure stock metrics
P/E
-0.85
P/B
7.31
EV/EBITDA
-0.66
RETURN ON EQUITY
-114.7%
NET MARGIN
0.0%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
28.1%
FLOAT SHARES
1,840,380
AVG. DAILY VOLUME (30D)
36,830
Insider transactions (SEC)
Exicure HiTron Inc.
Exicure HiTron Inc.
Exicure HiTron Inc.
Exicure HiTron Inc.
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Exicure stock
What does Exicure do?
Exicure, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Jungsoo Kim, the company employs around 1 people.
The IPO was on 22/05/2018; the stock trades on NASDAQ under the ticker XCUR.
What do analysts say about Exicure stock?
6 analysts rate the stock, the consensus is Buy (as of 16/08/2022).
The average price target is US$12.00, ranging from US$12.00 to US$12.00, with a median of US$12.00.
This is an external assessment, not a statement by Market Jury.
When does Exicure report next?
The next earnings date is 12/11/2026.
Around past earnings, price swings were roughly 19% stronger than usual.
Does Exicure pay a dividend?
No, Exicure currently does not pay a dividend.
Which stocks are comparable to Exicure?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Exicure stock analyzed?
Clicking "Analyze stock" lets five strategies assess Exicure against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.